Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNF -Inhibitor Treatment

  • End date
    Apr 16, 2023
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 21 July 2021
tumor necrosis factor
anti-rheumatic drugs
plaque psoriasis
psoriatic plaque
rheumatoid factor


The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNF-inhibitor treatment

Condition Psoriasis, PSORIATIC ARTHRITIS, Arthritis, Arthritis and Arthritic Pain, Psoriasis and Psoriatic Disorders, Arthritis and Arthritic Pain (Pediatric)
Treatment Secukinumab, ustekinumab
Clinical Study IdentifierNCT04632927
SponsorNovartis Pharmaceuticals
Last Modified on21 July 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of PsA as classified by CASPAR criteria for at least 6 months before randomization
Active PsA at baseline defined as 3 tender joints out of 68 and 3 swollen joints out of 66 (dactylitis of a digit counts as one joint each)
Inadequate response or intolerance to previous or current treatment with at least one TNF inhibitor
Inadequate response or intolerance to conventional disease modifying anti-rheumatic drugs (cDMARDs)
Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of 2 cm diameter and/or nail changes consistent with psoriasis and/or documented history of plaque psoriasis
Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies negative at screening

Exclusion Criteria

Pregnant or nursing women
Previous exposure to secukinumab, ustekinumab or any other biologic drug directly targeting IL-17, IL-17 receptor, IL-12 or IL-23
Patients for whom the use of secukinumab or ustekinumab is contraindicated
Use of any other investigational drug. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents
Evidence of ongoing infectious or malignant process
Subjects receiving high potency opioid analgesics
Ongoing use of prohibited psoriasis treatments/medications
Other protocol-defined inclusion/exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note